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DOI 10.1016/j.stem.2010.08.009Tumor-initiating cells (TICs) are defined
by their ability to form tumors after xeno-
transplantation in immunodeficient mice
and appear to be relatively rare in most
human cancers. Recent data in mela-
noma indicate that the frequency of
TICs increases dramatically via more
permissive xenotransplantation condi-
tions, raising the possibility that the true
frequency of TICs has been greatly under-
estimated in most human tumors. We
compared the growth of human pancre-
atic, non-small cell lung, and head and
neck carcinomas in NOD/SCID and NSG
mice. Although TIC frequency was de-
tected up to 10-fold higher in NSG mice,
it remained low (<1 in 2500 cells) in all
cases. Moreover, aldehyde dehydroge-
nase-positive (ALDH+) and CD44+CD24+
cells, phenotypically distinct cells en-
riched in TICs, were equally tumorigenic
in NOD/SCID and NSGmice. Our findings
demonstrate that TICs are rare in these
cancers and that the identification of
TICs and their frequency in other human
malignancies should be validated via
primary tumors and highly permissive
xenotransplantation conditions.
The cancer stem cell (CSC) hypothesis
proposes that clonogenic growth and
self-renewal potential are restricted to a
subset of cells within tumors. Central to
the hypothesis are tumor-initiating cells
(TICs), which are often defined by their
ability to form tumors after xenotransplan-
tation into immunodeficient NOD/SCID
mice and appear to be relatively rare in
most human cancers (Clarke et al.,
2006). However, recent data indicatethat the frequency of TICs can increase
dramatically when NOD/SCID mice lack-
ing the interleukin-2 receptor gamma
chain (NSG), which are more immunodefi-
cient than NOD/SCID mice, are used as
xenograft recipients or when syngeneic
mouse models of cancer are studied
(Kelly et al., 2007; Quintana et al., 2008).
These reports raise the possibility that
the true frequency of TICs has been
greatly underestimated in most human
tumors primarily because of xenotrans-
plantation barriers and the degree to
which immune recognition is impaired in
recipient mice. We compared the growth
of human pancreatic, non-small cell
lung, and head and neck squamous cell
carcinomas in NOD/SCID and NSG
mice. TIC frequency was up to 10-fold
higher in NSG mice for some tumors,
but remained relatively low (0.0028%–
0.04%) in all cases. Moreover, tumor
formation by pancreatic cancer aldehyde
dehydrogenase-positive (ALDH+) and
CD44+CD24+ cells, previously identified
as TICs (Li et al., 2007; Rasheed et al.,
2010), did not differ between NOD/SCID
or NSG mice. Our findings demonstrate
that TICs are rare in human pancreatic
adenocarcinoma, lung squamous cell
carcinoma, lung adenocarcinoma, and
head and neck squamous cell carcinoma,
despite the use of highly permissive
xenotransplantation conditions.
Specific modifications to the xeno-
transplantation protocol can dramatically
increase the frequency of human mela-
noma TICs from approximately 0.0001%
to 25% (Quintana et al., 2008; SchattonCell Stem Cell 7, Set al., 2008). These alterations include
the use of the more immunodeficient
NSG strain, injection of tumor cells in Ma-
trigel, and increasing the length of obser-
vation for tumor formation (>20 weeks).
We optimized our xenotransplantation
model to assess the TIC frequency for
fourmalignances and compared subcuta-
neous tumor formation in NSG and NOD/
SCID mice by performing limiting dilution
assays of tumor cells suspended in Matri-
gel. Animals were then monitored for
tumor growth for at least 20 weeks after
injection to assess tumor formation.
We investigated the frequency of TICs
in pancreatic adenocarcinoma, non-small
cell lung adenocarcinoma, squamous
cell lung carcinoma, and head and neck
squamous cell carcinoma by using NSG
mice. For each type of cancer, tumors
from at least three different patients
were analyzed. We found that the TIC
frequency ranged from 1/2,500 to
1/18,000 in pancreatic adenocarcinoma,
1/16,000 to 1/30,000 in non-small cell
lung adenocarcinoma, 1/4,200 to
1/16,000 in squamous cell lung carci-
noma, and 1/4,300 to 1/36,000 in head
and neck squamous cell carcinoma
(Table 1). Although TIC frequencies were
highly variable even within a specific diag-
nosis, they were relatively low (<0.04%) in
all of the tumors we tested.
We also compared the frequency of
TICs in NOD/SCID and NSGmice. Similar
to findings for melanoma (Quintana et al.,
2008), we found a trend toward de-
creased latency in NSG mice in all tumor
types (data not shown). However, TICeptember 3, 2010 ª2010 Elsevier Inc. 279
Table 1. Tumor-Initiating Capacity of Unsorted Pancreatic Adenocarcinoma, Lung Adenocarcinoma, Squamous Cell Lung Carcinoma,
and Head/Neck Squamous Cell Carcinoma Cells in NOD/SCID and NSG Mice
Tumor Formation
Tumor Type Case # Mouse Strain 106 105 3 3 104 104 5 3 103 103 5 3 102 102 TIC Frequency1 (95% CI) p Value
Pancreatic
adenocarcinoma
Panc253 NSG - - - - 2/4 1/4 0/4 - 6,600 (2,100–21,000) 0.19
NOD/SCID - - - - 4/4 1/4 0/4 - 2,500 (980–6,200)
Panc219 NSG - - - - 4/4 1/4 0/4 - 2,500 (980–6,200) 0.48
NOD/SCID - - - - 3/4 1/4 0/4 - 4,100 (1500–11,000)
Panc140 NSG - - - - 1/3 0/4 0/4 - 18,000 (2,700–127,000) 0.47
NOD/SCID - - - - 2/3 0/4 0/4 - 7,700 (2,000–30,000)
Lung adenocarcinoma ADC1 NSG - - - 2/4 - 0/4 - - 16,000 (4,000–68,000) -
NOD/SCID - 0/4 - 0/4 - 0/6 - - >100,000 (-)
ADC2 NSG - - - 2/4 - 0/4 - - 16,000 (4,000–68,000) 0.28
NOD/SCID - 4/4 - 0/4 - 0/4 - - 43,000 (14,000–131,000)
ADC3 NSG - - 2/4 2/4 - 0/4 - 0/4 30,000 (18,000–80,000) .62
NOD/SCID - 4/4 - 0/4 - 0/4 - - 43,000 (14,000–131,000)
Squamous cell lung
carcinoma
SCC1 NSG - - - 4/4 - 0/4 - - 4,200 (1,400–13,000) 0.002
NOD/SCID - 2/3 - 2/4 - 0/4 - - 51,000 (15,000–172,000)
SCC2 NSG - - - 2/4 - 0/4 - - 16,000 (4,000–68,000) 0.03
NOD/SCID - 1/4 - 2/4 - 0/4 - - 125,000 (34,000–453,000)
SCC3 NSG - - - 3/4 - 2/4 - - 4,600 (1,500–14,000) 0.003
NOD/SCID - 5/6 - 2/4 - 0/4 - - 42,000 (16,000–108,000)
Head/neck squamous
cell carcinoma
HN1 NSG 3/3 3/3 - 2/3 - 1/3 - 0/6 6,900 (1,900–25,000) 0.07
NOD/SCID 3/3 2/3 - 2/3 - 1/3 - 0/6 36,000 (10,000–133,000)
HN2 NSG - 2/3 - 2/3 - 1/3 - 0/4 36,000 (19,000–70,000) 0.78
NOD/SCID - 2/3 - 2/3 - 0/3 - 0/4 48,000 (13,000–170,000)
HN3 NSG - 5/5 - 5/5 - 0/5 - 0/5 4,300 (1,600–11,600) 0.67
NOD/SCID - 5/5 - 3/5 - 3/5 - 0/5 5,800 (2,100–15,600)
The TIC frequency was calculated via a limiting dilution analysis (Hu and Smyth, 2009) or L-Calc Software (Stem Cell Technologies) (with 95%
confidence intervals) and significance determined by chi-square analysis. See also Table S1 for TIC frequencies in subcutaneous versus orthotopic
injections and primary versus high-passage human non-small cell lung cancer xenografts.
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pancreatic adenocarcinoma or head and
neck squamous cell carcinoma cells
when measured in either strain of mice
(Table 1). By contrast, in all three cases
of squamous cell lung carcinoma, TICs
were more frequent when measured in
NSG mice compared with NOD/SCID
mice, ranging from 1/4,200 to 1/16,000
and 1/42,000 to 1/125,000 cells, respec-
tively (Table 1). Similarly, the TIC fre-
quency in 1 out of 3 cases of non-small
cell lung adenocarcinoma was higher
when assayed in NSG mice (Table 1). In
the lung adenocarcinoma in which a dif-
ference was detected, no tumors formed
at the highest dose of cells (100,000) in-
jected into NOD/SCID mice, whereas the
TIC frequency measured in NSG mice
was 1/16,000 (Table 1). In the two other280 Cell Stem Cell 7, September 3, 2010 ª20cases of non-small cell lung adenocarci-
noma, the TIC frequencies in both mouse
strains were not significantly different
(Table 1). Therefore, depending on the
specific cancer or among individual
tumors within a single diagnosis, TICs
may be detected up to 10-fold more
frequently in NSG than NOD/SCID mice,
but even then, remain quite rare.
Phenotypically distinct cells enriched in
tumorigenic capacity have been identified
in an increasing number of human malig-
nancies. However, in melanoma, when
more permissive experimental conditions
were used, specific phenotypes failed to
enrich for tumor-forming capacity (Quin-
tana et al., 2008). In pancreatic cancer,
both CD44+CD24+ and ALDH+ cells have
been identified as TICs (Li et al., 2007;
Rasheed et al., 2010). We isolated10 Elsevier Inc.CD44+CD24+ (0.2%–1.6% of total cells;
Figure S1 available online) and ALDH+
(2.3%–3.5% of total cells; Figure S1) cells
and compared tumor formation by each
of these cell populations in both models.
The TIC frequency was 1/300 and 1/330
(p = 0.471) for ALDH+ cells and 1/240
and 1/180 (p = 0.435) for CD44+CD24+
cells in NSG and NOD/SCID mice, re-
spectively (Table 2). Thus, CD44+CD24+
or ALDH+ cells were equally tumorigenic
in NOD/SCID and NSG mice, similar to
findings with bulk pancreatic cancer cells.
We also examined the histology of tumors
formed by both strains of mice and found
that they were all similar to the original
surgical specimen (Figure S2). These
data demonstrate that the degree of
immunodeficiency of the recipient mouse
strain does not alter the frequency or
Table 2. Tumor-Initiating Capacity of Sorted Pancreatic Cancer Cells in NOD/SCID and
NSG Mice
Tumor Formation
Cell Phenotype Mouse Xenograft 5000 1000 500 100
TIC Frequency1
(95% CI) p Value
ALDH+ NSG Panc253 4/4 3/4 1/4 300 (190–500) 0.471
Panc219 4/4 3/4 2/4
Panc140 4/4 2/4 2/4
NOD/SCID Panc253 4/4 4/4 2/4 330 (200–530)
Panc219 4/4 3/4 2/4
Panc140 3/4 1/4 0/4
CD44+CD24+ NSG Panc253 4/4 3/4 240 (130–450) 0.435
Panc219 2/2 3/4 1/4
Panc140 1/2 1/3
NOD/SCID Panc253 4/4 3/4 180 (100–330)
Panc219 2/2 3/4 4/4
Panc140 1/2 1/3
The TIC frequency was calculated with a limiting dilution analysis (with 95% confidence intervals)
and significance determined by chi-square analysis (Hu and Smyth, 2009). See Figure S1 for gating
strategy of sorted cells and histology of tumors.
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enriched tumorigenic potential.
We also examined whether the propor-
tion of TICs changed as tumors were
serially propagated as xenografts. In
non-small cell lung adenocarcinoma, TIC
frequency increased from 1/16,000–1/
30,000 in primary specimens to >1/10–1/
320 in extensively passaged tumors
(6–10 generations; Table S1). These find-
ings are similar to those recently reported
in melanoma (Boiko et al., 2010) and also
demonstrate our ability to detect and
quantify highly tumorigenic cells under
our xenograft conditions. Moreover, the
use of subcutaneous implantation did
not appear to negatively impact TIC fre-
quency, as indicated by the fact that
orthotopic intratracheal or intravenous
injections did not result in an increase in
TIC frequency (Table S2).
Our data demonstrate that TICs are
relatively infrequent in pancreatic adeno-
carcinoma, lung adenocarcinoma, squa-
mous cell lung carcinoma, and head and
neck squamous cell carcinoma. These
findings are in agreement with studies
of several other human malignancies
(Al-Hajj et al., 2003; Boiko et al., 2010;
Dalerba et al., 2007; Fang et al., 2005;
Lapidot et al., 1994; Li et al., 2007;
Matsui et al., 2004; Prince et al., 2007;
Rasheed et al., 2010; Schatton et al.,
2008; Singh et al., 2004; Suva` et al., 2009;
Yang et al., 2008). In contrast, Quintanaet al. (2008) recently reported that
approximately 25% of unselected mela-
noma cells are tumorigenic under more
permissive conditions (cells coinjected
with Matrigel in NSG mice). The variability
in these results may not be entirely due to
the use of xenotransplantation assays to
measure TIC frequency, because similar
findings have been observed in mouse
cancer models via syngeneic transplants
(Bruce and Van Der Gaag, 1963; Kelly
et al., 2007). An obvious explanation for
the differences in TIC frequency and
detection is the specific malignancy
studied. Clinically, melanoma sometimes
responds to immune-based therapeutics,
such as interferon-alpha or interleukin-2
(Smith et al., 2008), whereas these
approaches are generally ineffective for
most malignancies, including pancreatic
cancer (Bellone et al., 2006). Therefore,
residual immune cells, most probably NK
cells, in NOD/SCID mice decrease the
apparent TIC frequency in melanoma but
not in other cancers. Additional features,
such as tumor stage or grade, may also
affect the frequency of TICs in a specific
malignancy (Shackleton et al., 2009), and
recent findings have demonstrated that
metastatic melanoma lesions are rela-
tively enriched for TICs compared to
primary tumors (Boiko et al., 2010). The
tumors in our studies were all obtained
from patients with localized disease and
it remains to be seen whether TICCell Stem Cell 7, Sfrequency remain low in metastatic
pancreatic, lung, and head and neck
carcinomas.
Our findings also suggest that the use of
primary tumors or xenografts may influ-
ence TIC frequency. We found that TICs
were relatively rare in primary non-small
cell lung adenocarcinomas, but signifi-
cantly increased if tumors were heavily
passaged as xenografts. Similarly, a
recent report in melanoma (Boiko et al.,
2010) demonstrated increased TIC fre-
quency when melanomas were passaged
as xenografts, and these data may in part
explain the findings of the Quintana et al.
study (Quintana et al., 2008).
We also found that the distinct cellular
phenotypes (ALDH+ and CD44+CD24+)
that enrich for tumorigenic cells in NOD/
SCID mice are preserved in NSG mice.
These data suggest that a more permis-
sive xenotransplantation model does not
alter the functional characteristics of
specific populations enriched for TICs in
pancreatic cancer. However, the impact
of xenotransplantation into NSG rather
than NOD/SCID mice on the tumor-initi-
ating capacity of specific cell populations
in other malignancies remains to be seen.
The data presented here and previous
findings in melanoma emphasize the
need to study TICs within the context of
specific malignancies and disease states.
Supplemental Information
Supplemental Information includes Supplemental
Experimental Procedures, one figure, and one
table and can be found with this article online at
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